These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 21652029)

  • 1. Exenatide improves weight loss insulin sensitivity and β-cell function following administration to a type 2 diabetic HIV patient on antiretroviral therapy.
    Oriot P; Hermans MP; Selvais P; Buysschaert M; de la Tribonnière X
    Ann Endocrinol (Paris); 2011 Jun; 72(3):244-6. PubMed ID: 21652029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.
    Sheffield CA; Kane MP; Busch RS
    Pharmacotherapy; 2007 Oct; 27(10):1449-55. PubMed ID: 17896900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trial.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Pharmacotherapy; 2013 Aug; 33(8):817-26. PubMed ID: 23744726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of exenatide and metformin in combination on some adipocytokine levels: a comparison with metformin monotherapy.
    Derosa G; Cicero AF; Franzetti IG; Querci F; Carbone A; Ciccarelli L; D'Angelo A; Fogari E; Maffioli P
    Can J Physiol Pharmacol; 2013 Sep; 91(9):724-32. PubMed ID: 23984793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity.
    Preumont V; Hermans MP; Brichard S; Buysschaert M
    Diabetes Metab; 2010 Sep; 36(4):293-8. PubMed ID: 20447851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilizing effect of exenatide in a patient with C-peptide-negative diabetes mellitus.
    Paisley AN; Savage MW; Wiles PG
    Diabet Med; 2009 Sep; 26(9):935-8. PubMed ID: 19719716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exenatide therapy in insulin-treated type 2 diabetes and obesity.
    Nayak UA; Govindan J; Baskar V; Kalupahana D; Singh BM
    QJM; 2010 Sep; 103(9):687-94. PubMed ID: 20624837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapy and the quest for sustained improvements in β-cell health.
    Drucker DJ
    Diabetes Care; 2011 Sep; 34(9):2133-5. PubMed ID: 21868783
    [No Abstract]   [Full Text] [Related]  

  • 12. Incretin mimetics as a novel therapeutic option for hepatic steatosis.
    Tushuizen ME; Bunck MC; Pouwels PJ; van Waesberghe JH; Diamant M; Heine RJ
    Liver Int; 2006 Oct; 26(8):1015-7. PubMed ID: 16953843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incretins and other peptides in the treatment of diabetes.
    Todd JF; Bloom SR
    Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dipeptidyl peptidase-4 inhibitors in a type 2 diabetes patient with failure of glucagon-like peptide-1 receptor agonists.
    Wang Y; Zhao L; Huang Q; Peng Y
    J Diabetes; 2014 Mar; 6(2):164-6. PubMed ID: 23879890
    [No Abstract]   [Full Text] [Related]  

  • 15. Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea.
    Mari A; Nielsen LL; Nanayakkara N; DeFronzo RA; Ferrannini E; Halseth A
    Horm Metab Res; 2006 Dec; 38(12):838-44. PubMed ID: 17163361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of glucagon-like peptide-1 on the beta cell.
    Vilsbøll T
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide: its position in the treatment of type 2 diabetes.
    Guerci B; Martin CS
    Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study].
    De Block C; Paquot N; Daoudi N; Ballaux D; Van Gaal LF; Scheen AJ
    Rev Med Liege; 2009 Oct; 64(10):488-95. PubMed ID: 19911661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evidence-based and practical approach to using Bydureon™ in patients with type 2 diabetes.
    Painter NA; Morello CM; Singh RF; McBane SE
    J Am Board Fam Med; 2013; 26(2):203-10. PubMed ID: 23471935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.